Pursuing curative gene therapies to give patients and their families more bluebird days.
gene therapy • gene addition • sickle cell disease • beta-thalassemia • cerebral adrenoleukodystrophy
201 - 500
💰 $113.6M Post-IPO Equity on 2023-01
June 22
201 - 500
🇺🇸 United States – Remote
💵 $240k - $285k / year
💰 $113.6M Post-IPO Equity on 2023-01
⏱ Part Time
🔴 Lead
⚙️ Operations
🗽 H1B Visa Sponsor